Triple-negative breast cancer

OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

Retrieved on: 
Dienstag, November 13, 2018
Cancer, Clinical medicine, Medicine, Antineoplastic drugs, Breakthrough therapy, Bayer AG, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Pembrolizumab, Merck, Triple-negative breast cancer

SAN DIEGO and PENNINGTON, N.J., Nov. 13, 2018 /PRNewswire/ -- OncoSec Medical Inc., (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that TAVO will be featured in two poster sessions during the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4-8 in San Antonio, Texas.

Key Points: 
  • SAN DIEGO and PENNINGTON, N.J., Nov. 13, 2018 /PRNewswire/ -- OncoSec Medical Inc., (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that TAVO will be featured in two poster sessions during the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4-8 in San Antonio, Texas.
  • Posters include data on TAVO as a monotherapy and an initial project overview for KEYNOTE-890, a Phase 2 clinical trial in combination with Merck's KEYTRUDA (pembrolizumab) for the treatment of late stage triple negative breast cancer (TNBC).
  • In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates for use with its ImmunoPulse platform.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Virtual Humans in New App Help CDC Educate Breast Cancer Patients About Diagnosis & Treatment Options

Retrieved on: 
Mittwoch, Oktober 10, 2018
Breast cancer, Cancer, Health, Medicine, Triple-negative breast cancer, Triple Negative Breast Cancer Foundation, Inflammatory breast cancer

NEW YORK, Oct. 10, 2018 /PRNewswire-PRWeb/ -- For the first time, an app using virtual human technology is enabling newly diagnosed breast cancer patients to learn about their treatment options.

Key Points: 
  • NEW YORK, Oct. 10, 2018 /PRNewswire-PRWeb/ -- For the first time, an app using virtual human technology is enabling newly diagnosed breast cancer patients to learn about their treatment options.
  • Women with triple negative breast cancer have a 16% lower five-year survival rate compared to women with other types of breast cancer.
  • The new app, called Talk to Someone: Triple Negative Breast Cancer, gives patients the opportunity to navigate through questions about breast cancer and treatment, and get answers from an emotionally responsive virtual TNBC survivor named Linda.
  • "This app offers clear and accurate information to help women learn about their diagnosis and treatment options, so they can have more informed conversations with their doctors."

Global Triple-negative Breast Cancer Treatment Market Revenue to Cross US$ 720 Mn By 2026- Persistence Market Research

Retrieved on: 
Mittwoch, Oktober 3, 2018
Ribbon symbolism, Breast cancer, Triple-negative breast cancer, Treatment of cancer, Health

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market.

Key Points: 
  • These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market.
  • In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018.
  • This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.
  • Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.

TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC

Retrieved on: 
Freitag, September 28, 2018
Breast cancer, Triple-negative breast cancer, Investigational New Drug, Health, Medical research, Medicine

NANJING, China, Sept. 28, 2018 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).

Key Points: 
  • NANJING, China, Sept. 28, 2018 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).
  • Its unique profilegrants itsuperior efficacy against certain tumor types such as TNBC in extensive pre-clinical studies.
  • TNBC represents about 15% of all breast cancers.Thereexists a huge unmet medical need as there is currently no effective target therapy available for treating TNBC.
  • TransThera Biosciences, specializing in developing novel NCE drugs, was founded in 2016 in Nanjing, China.

BB&T's Barbara Duck named one of 2018's 'Women to Watch'

Retrieved on: 
Montag, September 24, 2018
Breast cancer, Triple-negative breast cancer

WINSTON-SALEM, N.C., Sept. 24, 2018 /PRNewswire/ -- BB&T Chief Information Officer (CIO) Barbara F. Duck has been named to American Banker's 25 "Women to Watch" list for 2018.

Key Points: 
  • WINSTON-SALEM, N.C., Sept. 24, 2018 /PRNewswire/ -- BB&T Chief Information Officer (CIO) Barbara F. Duck has been named to American Banker's 25 "Women to Watch" list for 2018.
  • Duck and other honorees will be celebrated on October 4, 2018 at a gala awards dinner at Cipriani Wall Street in New York City.
  • 17 on this year's list Duck's inclusion celebrates her transformational leadership style, philanthropic interests, and her personal triumph over breast cancer in 2017.
  • Duck was only seven months into her new role as CIO before being diagnosed with triple-negative breast cancer (TNBC).

HKBU Scholars in World-first Breakthrough for Difficult-to-treat Breast Cancer

Retrieved on: 
Mittwoch, August 29, 2018
RTT, Breast cancer, Cancer, Triple-negative breast cancer, Medicine, Clinical medicine, Bemcentinib

Chemists at Hong Kong Baptist University (HKBU) have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer (TNBC), one of the most difficult forms of breast cancer to treat.

Key Points: 
  • Chemists at Hong Kong Baptist University (HKBU) have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer (TNBC), one of the most difficult forms of breast cancer to treat.
  • The reported compound shows tremendous potential for the development of drugs for TNBC therapy.
  • The results of this study were published in the leading chemistry journalAngewandte ChemieInternational Edition.
  • Dr Edmond Ma said that KDM5A is overexpressed in breast cancer and other human cancers, including brain, lung and gastric cancers, thus promoting carcinogenesis and drug resistance.

OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer

Retrieved on: 
Dienstag, Juli 17, 2018
RTT, Cancer, Medicine, Clinical medicine, Breast cancer, Melanoma, Immunotherapy, Triple-negative breast cancer

The presentation, titled "Intra-tumoral delivery of tavokinogene telseplasmid (pIL-12) by electroporation: immunomodulation in melanoma and triple negative breast cancer," took place atthe 3rd Global Insight Conference on Breast Cancer in Valencia, Spain.

Key Points: 
  • The presentation, titled "Intra-tumoral delivery of tavokinogene telseplasmid (pIL-12) by electroporation: immunomodulation in melanoma and triple negative breast cancer," took place atthe 3rd Global Insight Conference on Breast Cancer in Valencia, Spain.
  • "We were grateful for the opportunity to present at the 3rd Global Insight Conference on Breast Cancer and share progress from our TAVO clinical programs with the clinicians, biotechnology executives, and industry opinion leaders in attendance.
  • OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse, for the treatment of cancer.
  • OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer.

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

Retrieved on: 
Donnerstag, Mai 24, 2018
RTT, Cancer, Anatomy, Oncolytic virus, Triple-negative breast cancer, Breast cancer, Prostate cancer

Calidi Biotherapeutics also appointed Allan J. Camaisa as its new CEO,to lead the organization towards successful drug discovery.

Key Points: 
  • Calidi Biotherapeutics also appointed Allan J. Camaisa as its new CEO,to lead the organization towards successful drug discovery.
  • "Calidi Biotherapeutics has developed a groundbreaking technology using potent oncolytic viruses for the treatment of cancer.
  • We are now focused on developing strategic partnerships and securing strong investments," said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics.
  • Calidi Biotherapeutics has active drug development programs targeting prostate and triple negative breast cancers.

OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

Retrieved on: 
Dienstag, Mai 8, 2018
RTT, Medicine, Clinical medicine, Cancer, Pembrolizumab, Triple-negative breast cancer, Immunotherapy, Melanoma, Breast cancer, Bemcentinib, IMP321

The planned clinical trial will evaluate the safety and efficacy of the combination in patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) who have previously failed at least one systemic chemotherapy or immunotherapy.

Key Points: 
  • The planned clinical trial will evaluate the safety and efficacy of the combination in patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) who have previously failed at least one systemic chemotherapy or immunotherapy.
  • Under the collaboration agreement, OncoSec will sponsor and fund the study and Merck will provide KEYTRUDA.
  • OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse, for the treatment of cancer.
  • OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer.